PRE Continues Astounding Growth, While Expanding Product Line

By Brad Sorensen, CFA NASDAQ: PRE READ THE FULL PRE RESEARCH REPORT Prenetics’ (NASDAQ: PRE) recent first quarter update added another layer to what is becoming one of the more aggressive growth stories in the consumer health and longevity space. While the main story is the extraordinary growth trajectory of IM8, company management also provided additional detail on its future product roadmap, announcing plans to launch three new SKUs in the fourth quarter of 2026, targeting hydration, creatine, and kids’ gummies. The significance of these launches extends beyond simply adding products to the lineup, as the company specifically emphasized that each category represents a very large addressable market capable of materially expanding IM8’s long-term revenue opportunity, again showing the company will not rest on its IM8 laurels alone. The first quarter itself showed exceptional momentum. Prenetics expects Q1 2026 revenue of approximately $36 million, with IM8 contributing roughly $33.8 million, representing sequential growth of more than 23% from Q4 2025 levels. Gross margins also improved meaningfully, rising to approximately 64%, reflecting increasing scale and operational leverage. Management further raised full-year 2026 IM8 revenue guidance to between $190 million and $210 million, suggesting confidence that growth is accelerating rather than slowing. One of the most notable aspects of the update was the company’s increasingly global revenue mix. By the end of the quarter, IM8 products were being shipped to 43 countries, with more than 60% of IM8 revenue generated outside the United States. The company identified the United States, Canada, the United Kingdom, Australia, and Singapore as its top five markets, illustrating that IM8 is evolving into an international premium wellness brand rather than a purely U.S.-focused supplement company. This diversification will become strategically important over time, as it reduces dependence on any single geography while opening opportunities for broader international scaling. Management also highlighted the success of its quarterly subscription strategy, which appears to be materially improving customer economics. Average order values have risen sharply, with new customer average order value reaching approximately $240 during Q1 2026 compared to roughly $110 during 2025. Subscription adoption remains extremely high at roughly 80% for new customers, helping establish recurring revenue visibility and stronger cash flow generation. Active Subscribers Show Rapid Growth We believe the announced planned expansion into hydration, creatine, and kids’ gummies is especially important because these are among the largest and fastest-growing categories within the global supplement industry. The sports hydration market alone is widely estimated to represent a multi-billion-dollar annual opportunity globally, benefiting from increasing consumer demand for performance and recovery products. Creatine has become one of the fastest-growing supplement categories in the broader wellness market, expanding well beyond bodybuilding into mainstream fitness, longevity, cognitive health, and healthy aging applications. Meanwhile, the global children’s gummy vitamin market has also grown rapidly as parents increasingly seek convenient nutritional supplementation products for children. Prenetics specifically framed these categories as “very large addressable markets,” suggesting the company believes these launches could substantially broaden IM8’s revenue base beyond its flagship Daily Ultimate Essentials platform. Importantly, and in contrast to many other players in the space, management emphasized that the new products will maintain the same premium science-backed positioning that has helped IM8 gain traction globally. That positioning has been reinforced through partnerships with David Beckham, Giannis Antetokounmpo, Aryna Sabalenka, Ollie Bearman, and, more recently, Inter Miami CF, which continue to enhance brand visibility and credibility worldwide. Another major strategic development during the quarter was Prenetics’ decision to completely divest its bitcoin holdings. The company sold its digital assets for approximately $41.3 million in proceeds and indicated that it would no longer pursue a bitcoin treasury strategy. Instead, management is redirecting capital toward IM8 growth initiatives and shareholder returns. We strongly support this move as it significantly simplifies the business by focusing the company squarely on consumer health and operational execution rather than cryptocurrency exposure. Prenetics has simultaneously become more aggressive in returning capital to shareholders. The company disclosed that it has already executed approximately $19 million of its previously announced $40 million share repurchase authorization. Management has indicated that the strengthened balance sheet and proceeds from the bitcoin divestiture could support additional shareholder-friendly actions going forward. Overall, the first quarter update reinforced the view that Prenetics is evolving rapidly into a focused global consumer health company centered around the IM8 platform. Revenue growth, rising margins, international expansion, recurring subscription revenue, and the planned entry into several massive supplement categories all point toward a company attempting to build a diversified premium wellness ecosystem rather than a single-product brand. If management can successfully execute on the upcoming hydration, creatine, and kids’ gummies launches while sustaining current growth rates, the addressable market opportunity for IM8 could become substantially larger than investors initially anticipated and lead to a significant rerating of PRE stock. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.